Canna~Fangled Abstracts

Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway

By April 9, 2021April 11th, 2021No Comments
Review

. 2021 Apr 9.
doi: 10.1038/s41380-021-01086-1.

Online ahead of print.
Alexandre Vallée 1, Yves Lecarpentier 2, Jean-Noël Vallée 3 4
Affiliations 

Abstract

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and glutamatergic pathways play key roles in the causes of OCD. However, first-line therapies include cognitive-behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for new treatment is mandatory. This review focuses on the potential effects of cannabidiol (CBD), as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which CBD provides its benefit properties. CBD medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway and circadian rhythms dysregulation in OCD. Future prospective clinical trials could focus on CBD and its different and multiple interactions in OCD.

References

    1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:53–63. – PubMed – DOI
    1. Bokor G, Anderson PD. Obsessive-compulsive disorder. J Pharm Pract. 2014;27:116–30. – PubMed – DOI
    1. Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, et al. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder. Mol Psychiatry. 2014;19:1025–30. – PubMed – PMC – DOI
    1. Alici D, Bulbul F, Virit O, Unal A, Altindag A, Alpak G, et al. Evaluation of oxidative metabolism and oxidative DNA damage in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2016;70:109–15. – PubMed – DOI
    1. Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, et al. Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry. 2017;74:833–40. – PubMed – PMC – DOI

Publication types

Leave a Reply